Table 4.
Clinical trials with consolidative, frontline autologous hematopoietic stem-cell transplantation (ASCT) in patients with primary central nervous system lymphoma.
| Reference | n | Induction regimen | Response prior to ASCT (%) | Median follow up (months) | Overall survival |
|---|---|---|---|---|---|
| Yoon et al. [2011] | 11 | MTX/Ara-C | CR: 91 | 25 | Median survival NR |
| Illerhaus et al. [2008] | 13 | MTX, Cy, Thiotepa | CR: 54 | 25 | 3-year OS 77% |
| Colombat et al. [2006] | 25 | MTX, etoposide, carmustine | CR: 52 | 34 | 4-year OS 64% |
| Kiefer et al. [2012] | 23 | MTX | CR: 70 | 117 | 9-year OS 35% |
| Brevet et al. [2005] | 6 | MBVP | CR: 100 | 41.5 | 2-year OS 40% |
| Abrey et al. [2003] | 28 | MTX/Ara-C | CR: 29 | 28 | 2-year OS 55% |
Ara-C, cytarabine arabinoside; CR, complete response; Cy, cyclophosphamide; MBVP, methotrexate, carmustine, etoposide, methylprednisolone; MTX, methotrexate; NR, not reached; OS, overall survival.